We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The National Institutes of Health (NIH) is starting a late-stage trial of two existing drugs and one investigational agent to assess their potential to control cytokine storm, an immune system overreaction in COVID-19 patients. Read More
HHS Deputy Chief of Staff for Policy Paul Mango said that within 24 to 48 hours after an Emergency Use Authorization is granted for a COVID-19 vaccine, “we expect to be putting needles in people’s arms.” Read More
Pfizer will not be ready to submit an Emergency Use Authorization (EUA) application for its COVID-19 vaccine candidate until late in November, CEO Albert Bourla has announced, despite his previous projections of possibly filing for an EUA this month. Read More
Gilead Sciences has rejected early findings from the World Health Organization’s Solidarity trial showing four antivirals, including remdesivir, had “little or no effect” on hospitalized COVID-19 patients, criticizing the trial’s design and expressing concern that the data hadn’t gone through a peer review. Read More
UK-based contract research organization Open Orphan said it is in advanced negotiations with the British government and other partners for a human challenge trial of a COVID-19 vaccine. Read More